Propargylglycine (64165-64-6) is an irreversible inhibitor of the hydrogen sulfide biosynthesis enzyme, cystathione-γ-lyase. It inhibits H2S production in rat liver preparations (IC50=55 μM) and inhibits the rise in plasma H2S in rats with hemorrhagic shock2. Propargylglycine reduces inflammation in a rodent carrageenan-induced hindpaw edema model3 and ameliorates gentamycin-induced nephrotoxicity1.
White to off-white powder
Dl-propargylglycine is an inhibitor of hydrogen sulfide (H2S) production.
DL-Propargylglycine (PAG) is an irreversible inhibitor of the enzyme cystathionine γ-lyase (GCL), a key enzyme involved in glutathione synthesis and the metabolic transsulfuration pathway which regulates homocysteine concentration and mediates cysteine synthesis. Treatment of animal disease models with PAG was shown to alleviate symptoms of diseases that impair the formation or action of hydrogen sulfide (H2S).
1) Dam et al. (2012), Inhibition of cystathione gamma-lyase and the biosynthesis of endogenous hydrogen sulphide ameliorates gentamicin-induced nephrotoxicity; Eur. J. Pharmacol., 685 165
2) Mok et al. (2004), Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis; Br. J. Pharmacol., 143 881
3) Bhatia et al. (2005),Hydrogen sulphide is a mediator of carrageenan-induced hindpaw edema in the rat; Br. J. Pharmacol., 145 141
